Effective rituximab treatment in primary Sjogren's syndrome: A randomised,double-blind, placebo-controlled trial.

Trial Profile

Effective rituximab treatment in primary Sjogren's syndrome: A randomised,double-blind, placebo-controlled trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2015

At a glance

  • Drugs Rituximab (Primary)
  • Indications Sjogren's syndrome
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 09 Jun 2012 Results assessing changes from baseline in immunoglobulin free light chain concentrations presented at the 13th Annual Congress of the European League Against Rheumatism.
    • 04 Nov 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 28 May 2011 Interim results reporting the effects of treatment on BAFF levels were presented at the 12th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top